Asia Pacific Gastric Cancer Market Size, Share & Industry Trends Analysis Report By Route of Administration (Injectable and Oral), By Treatment Type, By Disease Type, By Distribution Channel, By Drug Class, By Country and Growth Forecast, 2023-2029

The Asia Pacific Gastric Cancer Market should witness market growth of 18.1% CAGR during the forecast period (2023-2029).

Rapid regulatory authority approval of treatments for gastric cancer may offer the market for these drugs tremendous growth potential. In addition, the creation of new medications and treatments is greatly aided by research & development activities. Rapid improvements in cutting-edge diagnostic equipment may lead to an increase in the use of gastric cancer medications. As a result, the market for gastric cancer will have tremendous growth prospects as people become more aware of the signs and causes of gastric cancer. Additionally, prospective pipeline candidates will significantly accelerate the market's growth rate for medications that treat gastric cancer.

One of the main factors influencing the gastric cancer market is the ageing population. As the population ages, the need for therapies for gastric cancer is anticipated to rise. As people live longer, their risk of having gastric cancer rises. Gastric cancer is the sixth most frequent cancer worldwide and is more common in males than women, as reported by the World Health Organization. The prognosis for people with gastric cancer can be significantly improved by early detection and therapy. Other factors anticipated to drive the gastric cancer market include improvements in diagnosis and treatment and growth in healthcare spending.

Chemotherapy is the most popular treatment choice in nations like China, but a robust product pipeline and the anticipated approval of the treatments will support regional growth throughout the forecast period. The stage or phase of cancer at the time of diagnosis significantly impacts the likelihood of survival for stomach cancer. The survival rate increases with earlier illness development stages. In Asia Pacific, geriatric people make up the majority of the cases that are discovered at a later stage of the disease. An increase in stomach cancer cases directly correlates with the region's aging population growth. Over the projection period, the market for gastric cancer therapies will develop due to this aspect and the rising health awareness-driven desire for early detection.

The China market dominated the Asia Pacific Gastric Cancer Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $761.1 million by 2029. The Japan market is experiencing a CAGR of 17.3% during (2023-2029). Additionally, The India market would display a CAGR of 18.9% during (2023-2029).

Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, and Radiation Therapy & Surgery. Based on Disease Type, the market is segmented into Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor, Lymphoma and Others. Based on Distribution Channel, the market is segmented into Specialty & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Pfizer, Inc., Viatris, Inc. (Mylan N.V.), F. Hoffmann-La Roche Ltd., Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., and Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.).

Scope of the Study

By Route of Administration

• Injectable
• Oral

By Treatment Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy & Surgery

By Disease Type

• Adenocarcinoma
• Carcinoid Tumor
• Gastrointestinal Stromal Tumor
• Lymphoma
• Others

By Distribution Channel

• Specialty & Retail Pharmacies
• Hospital Pharmacies
• Others

By Drug Class

• PD-1/PD-L1 Inhibitors
• HER2 Antagonists
• VEGFR2 Antagonists
• Others

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Novartis AG
• Pfizer, Inc.
• Viatris, Inc. (Mylan N.V.)
• F. Hoffmann-La Roche Ltd.
• Eli Lilly And Company
• Merck & Co., Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bristol Myers Squibb Company
• Celltrion Healthcare Co., Ltd.
• Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free